Investors

Home / Investors / Overview

Company Information

CymaBay Therapeutics (Nasdaq: CBAY)

We are a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need. We are evaluating seladelpar in primary biliary cholangitis (PBC) and NonAlcoholic SteatoHepatitis (NASH). We also have two product programs in earlier development that feature unique mechanisms of action and have potential in liver and chronic diseases.

Stock Information


Last Change Volume

Shares Outstanding: 10,064,495
(as of March 3, 2014)

Company Information

CymaBay Therapeutics
7575 Gateway Blvd
Suite 110
Newark, CA 94560

Investor Relations

Sujal Shah
(510) 293-8800
investors@cymabay.com

Recent News

17Sep

CymaBay Therapeutics Announces Departure of Chief Medical Officer

3Sep

CymaBay Therapeutics to Present at Upcoming Investor Conferences in September

7Aug

CymaBay Reports Second Quarter 2019 Financial Results and Provides Corporate Update

Upcoming Event

Sep 24 2019 8:00 am ET

Oppenheimer Fall Summit Focused on Specialty Pharma & Rare Disease Companies

September 24, 2019 at 8:00 am ET

Q2 2019 Quarterly Results